Psyence Biomedical (PBM) Net Income towards Common Stockholders (2023 - 2025)

Psyence Biomedical's Net Income towards Common Stockholders history runs 3 years deep, the most recent figure standing at -$1.5 million for Q3 2025.

• In Q3 2025, Net Income towards Common Stockholders fell 230.18% year-over-year to -$1.5 million; the TTM figure through Sep 2025 stood at -$348875.0 (changed N/A YoY), while the FY2025 annual figure was -$3.7 million, down 232.97% from the prior year.
• Net Income towards Common Stockholders was -$1.5 million for Q3 2025 at Psyence Biomedical, down from $1.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $1.2 million in Q3 2024 to a low of -$3.2 million in Q1 2023.
• Historically, Net Income towards Common Stockholders has averaged -$1.2 million across 3 years, with a median of -$1.5 million in 2025.
• Biggest YoY gain for Net Income towards Common Stockholders was 230.18% in 2025; the steepest drop was 230.18% in 2025.
• A 3-year view of Net Income towards Common Stockholders shows it stood at -$3.2 million in 2023, then jumped by 135.74% to $1.2 million in 2024, then sank by 230.18% to -$1.5 million in 2025.
• The last three Net Income towards Common Stockholders figures came in at -$1.5 million (Q3 2025), $1.2 million (Q3 2024), and -$3.2 million (Q1 2023), per Business Quant data.